| Patent Number |
Title Of Patent |
Date Issued |
| 7407651 |
IFN-.beta. liquid formulations |
August 5, 2008 |
| Interferon-beta liquid formulations stabilized with a polyol, a non-reducing sugar or a amino acid. In particular, the formulations are stabilized with a polyol, such as mannitol. The formulations, preferably, furthermore comprise a buffer, such as acetate buffer, at a pH comprised b |
| 7364910 |
Methods of inducing ovulation |
April 29, 2008 |
| The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the ph |
| 7317095 |
Mutant glycoproteins |
January 8, 2008 |
| The inventors have designed novel FSH mutants with increased glycosylation and longer half-lives for use in inducing folliculogenesis in human patients. The use of a FSH mutant preparation of the invention permits the use of lower cumulative doses of FSH to achieve the same or better |
| 7317002 |
Site-specific preparation of polyethylene glycol-GRF conjugates |
January 8, 2008 |
| A method is described for the site-specific preparation of hGRF-PEG conjugates containing one or more PEG units (per mole of hGRF) covalently bound to Lys.sup.12 and/or Lys.sup.21 and/or N.sub..alpha., characterized in that the conjugation reaction between the hGRF peptide and activated |
| 7282352 |
Homogeneity and secretion of recombinant proteins in mammalian systems |
October 16, 2007 |
| The present invention relates to a method for improving homogeneity and/or secretion of a recombinant protein of interest expressed in mammalian cells by replacing the endogenous signal peptide sequence of the DNA encoding the protein of interest with that of human hGH. Specifically, |
| 7276531 |
G-lactam derivatives as prostaglandin agonists |
October 2, 2007 |
| A gamma-lactam diene of Formula I: ##STR00001## which is particularly useful as a medicament for the treatment of various disorders such as asthma, hypertension, osteoporosis, sexual dysfunction and fertility disorders. |
| 7268210 |
PEG-LHRH analog conjugates |
September 11, 2007 |
| PEG-LHRH analog conjugates, where a PEG moiety is covalently bound to a serine residue of a LHRH analog, and methods for producing these conjugates are provided in the present invention. Also provided are a pharmaceutical composition and a method for treating pathologies in which LHR |
| 7259162 |
Benzazole derivatives and their use as JNK modulators |
August 21, 2007 |
| The present invention is related to benzazole derivatives notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such benzazole derivatives. Said benzazole derivatives are efficient modulators of the JNK pathway, they are in particu |
| 7258997 |
Methods of increasing protein expression levels |
August 21, 2007 |
| The present invention relates to methods of increasing protein expression levels whereby at least one amino acid in a protein amino acid sequence is substituted for the amino acid, proline. Preferably, the substitution occurs within 15 amino acids, more preferably within 10 amino acids a |
| 7256321 |
Intracellular modulators of apoptopic cell death pathways |
August 14, 2007 |
| A DNA sequence encoding a glucocorticoid-induced leucine-zipper family related protein (GILR), isoforms, fragments or analogs thereof, said GILR, isoforms, fragments or analogs thereof capable of inhibiting apoptosis and stimulating lymphocyte activity, GILR proteins, isoforms, analo |
| 7253199 |
Azole derivatives and pharmaceutical compositions containing them |
August 7, 2007 |
| The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing various cancers, |
| 7223732 |
Compound B as an angiogenic agent in combination with human growth factors |
May 29, 2007 |
| Compound B is shown to promote angiogenesis, specifically, budding of capillaries. The combination of Compound B and with human growth factor, such as bFGF, shows synergistic angiogenetic effects. |
| 7217687 |
Use of osteopontin for the treatment and/or prevention of neurologic diseases |
May 15, 2007 |
| The invention relates to the use of osteopontin, or of an agonist of osteopontin activity, for treatment or prevention of a neurologic diseases. |
| 7211601 |
Pharmaceutically active pyrrolidine derivatives |
May 1, 2007 |
| The present invention is related to pyrrolidine derivatives of formula (I). Said ##STR00001## compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of premature labor, |
| 7201896 |
IL6RIL6 chimera for the treatment of neurodegenerative diseases |
April 10, 2007 |
| The invention relates to the use of IL6RIL6 chimera in the treatment and prevention of neurological diseases and disorders. |
| 7189754 |
Pyrrolidine ester derivatives with oxytocin modulating activity |
March 13, 2007 |
| The present invention is related to the use of pyrrolidine esters of formula (I) for the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to the use of pyrrolidine esters of formula (I) to modulate, nota |
| 7157239 |
Method and kit for identifying and/or quantifying radiolabeled aminoglycoside binding molecules |
January 2, 2007 |
| The present invention describes novel methods, assays and kits for identifying and/or quantifying Aminoglycoside Binding Molecules (ABMs), enzymes modifying such molecules, and compounds modulating the interaction between ABMs and either enzymes or aminoglycosides, by exploiting the |
| 7151083 |
Luteinizing hormone and follicle stimulating hormone for use in inducing folliculogenesis |
December 19, 2006 |
| The present invention relates to the use of gonadotrophins in the induction of folliculogenesis in anovulatory women. In particular, it relates to the use of LH (or an equivalent dosage of hCG) in the production of a medicament for inducing folliculogenesis in anovulatory women at a |
| 7115754 |
Pyrrolidine derivatives as oxytocin antagonists |
October 3, 2006 |
| The present invention relates to novel pyrrolidine derivative of formula (I), its geometrical isomers, its optically active forms as enantiomers, diastereomers, mixtures of these and its racemate forms, as well as salts thereof, wherein R.sup.1 is selected from the group comprising or |
| 7115639 |
Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists |
October 3, 2006 |
| The present invention is related to pyrrolidine oxadiazole and thiadiazole derivatives for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such pyrrolidine oxadiazole derivatives. Said pyrrolidine derivatives are useful in the treatment and |
| 7078236 |
Methods of inducing ovulation |
July 18, 2006 |
| The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the ph |
| 7053228 |
Sulfur analogues of 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) for treating excess of glucocor |
May 30, 2006 |
| The present invention is related to novel 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) analogues, their use as antiglucocorticoids for the treatment and/or prophylaxis of disease associated to an excess of glucocorticoids. In particular, the invention relates to the use of novel 21-h |
| 7053054 |
Purified LH |
May 30, 2006 |
| A process for the purification of recombinant human Luteinizing Hormone (LH) from a sample of crude recombinant LH in the supernatant of CHO cells comprises the combined use of the ion-exchange chromatography and reverse phase HPLC. The ion-exchange chromatography and the reverse phase |
| 7018988 |
Pharmaceutically active pyrrolidine derivatives as Bax inhibitors |
March 28, 2006 |
| The present invention is related to new substituted pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of neurodegenerat |
| 7012060 |
TNF receptor and steroid hormone in a combined therapy |
March 14, 2006 |
| The present invention relates to the use of a TNF Receptor together with a steroid hormone to produce a pharmaceutical composition for the treatment of lethal bacterial and viral infections as well as autoimmune and inflammatory diseases. It also relates to said pharmaceutical compos |
| 6996474 |
Automated method for identifying related biomolecular sequences |
February 7, 2006 |
| The invention relate to an automated method for identifying related biomolecular sequences having defined features of interest from databases, the databases comprising at least a first and a second set of sequences, each set being derived from a different type of organism, comprising |
| 6991938 |
Method of assay |
January 31, 2006 |
| A kinetic assay method for quantifying an analyte in a sample. |
| 6977071 |
Amino-terminally truncated RANTES as chemokine antagonists |
December 20, 2005 |
| The present invention relates to amino-terminally truncated RANTES, lacking NH.sub.2 -terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their |
| 6962925 |
Benzo(C)quinolizine derivatives and their use as 5.alpha.-reductases inhibitors |
November 8, 2005 |
| A fully and partially reduced benzo(c)quinolizine compound of formula (1): ##STR1## |
| 6953774 |
Methods of inducing ovulation |
October 11, 2005 |
| The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the ph |
| 6914121 |
PEG-LHRH analog conjugates |
July 5, 2005 |
| PEG-LHRH analog conjugates, where a PEG moiety is covalently bound to a serine residue of a LHRH analog either directly or via a bifunctional linker molecule, such as an amino acid, and methods for producing these conjugates are provided in the present invention. Also provided are a |
| 6914069 |
Pharmaceutically active compounds and methods of use |
July 5, 2005 |
| The invention provides substituted pyrazole compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for the treatment of mammalian infertility. |
| 6905676 |
Amino-terminally truncated MCP-2 as chemokine antagonists |
June 14, 2005 |
| The present invention relates to amino-terminally truncated MCP-2, lacking NH.sub.2 -terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3, 1-4 or 1-5 of the naturally-occurring MCP-2 and having chemokine antagonistic activity, as well as cDNA sequences encoding them, the |
| 6902728 |
Chemokine receptor antagonist and cyclosporin in combined therapy |
June 7, 2005 |
| The use of a chemokine receptor antagonist together with a cyclosporin to produce a pharmaceutical composition for treating or preventing rejection of transplanted organs, tissues or cells is herein disclosed. Said pharmaceutical compositions for the simultaneous, sepatate or sequential |
| 6869932 |
Site-specific preparation of polyethlene glycol-GRF conjugates |
March 22, 2005 |
| A method is described for the site-specific preparation of hGRF-PEG conjugates containing one or more PEG units (per mole of hGRF) covalently bound to Lys.sup.12 and/or Lys.sup.21 and/or N.sub..alpha., characterized in that the conjugation reaction between the hGRF peptide and activated |
| 6855684 |
Compound B as angiogenic agent in combination with human growth factors |
February 15, 2005 |
| The present invention refers to the use of Compound B as angiogenic agent in combination with human growth factors. |
| 6852314 |
IFN-.beta. liquid formulations |
February 8, 2005 |
| Interferon-.beta. liquid formulations stabilized with a polyol, a non-reducing sugar or an amino acid. In particular, the formulations are stabilized with a polyol, such as mannitol. The formulations, preferably, furthermore comprise a buffer, such as acetate buffer, at a pH comprised |
| 6849720 |
Monoclonal antibodies to the human LDL receptor, their production and use |
February 1, 2005 |
| There are provided monoclonal antibodies to the LDL receptor which are useful for the identification and purification of LDL and in treatment of e.g. hepatitis C infection. |
| 6838433 |
IL-6 antagonist peptides |
January 4, 2005 |
| The present invention relates to IL-6 antagonist peptides, isolatable from a peptide library through the two-hybrids system by their ability to bind to the intracellular domain of gp130 and containing at least 5 amino acids. In particular, such peptides comprise the amino acid sequence S |
| 6833348 |
Intracellular glucocorticoid-induced leucine zippers modulators of apoptic cell death pathways |
December 21, 2004 |
| A DNA sequence encoding a glucocorticoid-induced leucine-zipper family related protein (GILR), isoforms, fragments or analogs thereof said GILR, isoforms, fragments or analogs thereof capable of inhibiting apoptosis and stimulating lymphocyte activity, GILR proteins, isoforms, analogs, |
| 6770656 |
Amine derivatives for the treatment of apoptosis |
August 3, 2004 |
| The present invention is related to substituted amine derivatives notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such amine derivatives of formula (I). Said substituted amine derivatives are efficient modulators, in particular |
| 6723850 |
Process for the synthesis of (1-H)-benzo[c]quinolizin-3-ones derivatives |
April 20, 2004 |
| The present invention refers to a process for the preparation of (1H)-benzo[c]quinolizin-3-ones derivatives of general formula (I) which involves only three steps and the use, as starting products, of commercially available, or easily preparable, compounds. The compounds of formula ( |
| 6696063 |
Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrop |
February 24, 2004 |
| Pathological regional adipose tissue accumulation associated with HIV-associated dysmorphic/dysmetabolic syndrome (HADDS) which may occur with or without subcutaneous adipose tissue lipodystrophy (and which is also described as HIV-associated adipose redistribution syndrome or HARS a |
| 6663867 |
Hybrid heterodimeric protein hormone comprising a TNF binding protein and a glycoprotein hormone |
December 16, 2003 |
| A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-.beta. and TPO, linked to a subunit of a heterodimeric proteinaceous hormone, such as hCG. Each |
| 6663865 |
Tumor necrosis factor antagonists and their use in endometriosis |
December 16, 2003 |
| Tumor necrosis factor antagonists are administered in therapeutically effective doses to treat and/or prevent endometriosis. The antagonists of this invention typically are selected from among several classes but preferably are soluble TNF receptors. The antagonists are useful for the |
| 6660848 |
Allelic variant of human STAT3 |
December 9, 2003 |
| A predominant allelic variant of the human STAT3 protein, the cDNA sequence encoding it, its use in therapy and/or in diagnosis of autoimmune and/or inflammatory diseases, as well as pharmaceutical compositions comprising it. |
| 6645171 |
Reconstituting device for injectable medication |
November 11, 2003 |
| A device for reconstituting liquid for medical use by bringing together a first liquid medium contained in a first vessel in the form of a cartridge (3) and a second medium, such as a drug in solid form, contained in a second vessel in the form of a vial (7), the device (19) comprising m |
| 6638500 |
Polyol-IFN-.beta.conjugates modified at Cys-17 and composition containing same |
October 28, 2003 |
| PEG-IFN-.beta. conjugates, where a PEG moiety is covalently bound to Cys.sup.17 of human IFN-.beta., are produced by a process of site specific PEGylation with a thiol reactive PEGylating agent. A pharmaceutical composition and a method for treating infections, tumors and autoimmune |
| 6608044 |
Inhibition of TNF activity |
August 19, 2003 |
| The bioactivity of TNF is inhibited by administering heparin or a derivative thereof along with a soluble TNF receptor. The heparin or derivative thereof can be administered simultaneously with the soluble TNF receptor, either in separate compositions or in compositions containing bo |
| 6599875 |
IL-6 antagonist peptides |
July 29, 2003 |
| The present invention relates to IL-6 antagonist peptides, isolatable from a peptide library through the two-hybrids system by their ability to bind to the intracellular domain of gp 130 and containing at least 5 amino acids. In particular, such peptides comprise an amino acid sequence, |
